**Research Article**

# Association Study of the *PTPN22* Gene Polymorphisms with Systemic Lupus Erythematosus in Lorestan Province of Iran

Seyedeh Zahra Shahrokhi,[1] Seyed Reza Kazemi Nezhad,[1,*] Sharam Baharvand Ahmadi,[2] and Mohammad Reza Akhoond[3]

[1]Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, IR Iran
[2]Department of Internal Medicine, School of Medicine, Aja University of Medical Sciences, Tehran, IR Iran
[3]Department of Statistics, Faculty of Mathematical Sciences and Computer, Shahid Chamran University of Ahvaz, Ahvaz, IR Iran

[*] *Corresponding author*: Seyed Reza Kazemi Nezhad, PhD, Associate Professor, Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, IR Iran. Tel/Fax: +98-6133338965, E-mail: kazemi_reza@scu.ac.ir

## Abstract

**Background:** The protein tyrosine phosphatase non-receptor 22 (*PTPN22*) gene encodes the lymphoid protein tyrosine phosphatase. Recent studies demonstrated the association between the +1858C > T, -1123G > C variants of *PTPN22* gene, and different autoimmune diseases. The current study aimed at examining the association between the polymorphism of *PTPN22* gene and systemic lupus erythematosus (SLE) in the Southwest of Iran.

**Methods:** The current study included 120 patients with SLE and 120 healthy volunteers as a control group. Genomic DNA was extracted and the genotyping was performed based on the PCR-restriction fragment length polymorphism (PCR-RFLP) method.

**Results:** Frequency of 1858T allele (P < 0.001, OR = 0.44, 95% CI = 0.291 to 0.663)showed association and frequency of 1123C allele (P = 0.307, OR = 0.811, 95% CI = 0.543 to 1.212)showed no association with SLE in patients compared with the control group in the studied population.

**Conclusions:** Statistical analysis showed no relationship among gender, genotype, and SLE risk. However, there was a significant relationship between age and the SLE risk (P = 0.006).

*Keywords:* Polymorphism, Systemic Lupus Erythematosus, *PTPN22* Gene

## 1. Background

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with clinical involvement that can affect human body organs or systems, especially skeletal muscles, kidney, heart, skin, and central nervous system (CNS)(1, 2). The prevalence of SLE in human population was reported about 20 to 150 cases per 100,000 people. Females affect10 times more than males by the SLE disease (3). SLE has a complex and strong genetic basis. Molecular genetic studies in humans and animals identified the important genes that contribute the pathogenesis of SLE. The most important genes predispose to disease are human leukocyte antigens (HLA) such as DR3, DR4, followed by non-HLA like protein tyrosine phosphatase non-receptor type 22 (*PTPN22*), signal transducer, activator of transcription 4 (STAT4), and interferon regulatory factor 5. Among non-HLA genes, *PTPN22* is considered as the most effective gene in autoimmune diseases (4, 5).

SLE has various clinical appearances with a large number of autoantibodies. So far, more than 180 autoantibodies were identified in the blood of patients with SLE, although different people may show different antibody profiles (6). Currently, the clinical diagnosis of lupus relied on the presence of at least 4 out of 11 diagnostic criteria proposed by the American College of Rheumatology (ACR) for SLE (7). The presence of anti-nuclear antibodies (ANA) in patient's serum is the most important laboratory criterion for the diagnosis of SLE. The most important characteristic of autoantibodies in SLE is targeting nuclear fusion, anti-nuclear antibodies (ANA), and antibodies against double-stranded DNA (ds-DNA), which is positive in more than 90% of the patients with SLE (2).

Various studies showed that *PTPN22* gene contributes in predispose to autoimmune diseases (8, 9). The *PTPN22* gene is located on chromosome 1p13 and encodes the lymph protein tyrosine phosphatase (LYP), which plays an important role in controlling signaling through T-cell receptor and negative control of T-cell activating in the later stages (8). B- and T-lymphocytes dysfunction is usually observed in patients with SLE and many studies recorded defects in B- and T-cell receptors signal transduction (10). The

most common single-nucleotide polymorphism (SNP) in *PTPN22* is (1858C > T) rs2476601. In this SNP, a missense mutation in nucleotide position 1858 in the coding area of gene converts cytosine into thymine, causing the single amino acid arginine to be converts into tryptophan in position 620 in exon 14 (11, 12). Another SNP in gene *PTPN22* is rs2488457 (-1123G > C) in which a missense mutation in nucleotide position 1123 in promoter area converts guanine to cytosine (13). The *PTPN22* mutations may cause T-cell activation and the induction of autoimmune diseases such as SLE, rheumatoid arthritis, autoimmune thyroid, and type 1 diabetes mellitus (T1DM)(14). Therefore, the probable association between +1858C > T and -1123G > C polymorphisms in *PTPN22* promoter was studied in the current study among patients with SLE living the Southwest of Iran.

## 2. Methods

### 2.1. Study Population

The study was conducted on 120 patients with SLE confirmed by a rheumatologist and the positive profile of ANA and anti-dsDNA. Also, 120 healthy persons without a family history of autoimmune diseases, matched for age and gender, were selected as controls. In the study, all patients and controls were selected from Lorestan province in Southwest of Iran. The study was approved by the ethics committee of Khoramabad University of Medical Sciences, Khorramabad, Iran, and was conducted after obtaining the written informed consent from all participants.

### 2.2. Genotyping

Genomic DNA was extracted out of the subjects' blood samples using the salting-out method and genotype was assessed using the PCR-restriction fragment length polymorphism (PCR-RFLP) method (15). Primers used to identify mutations of +1858C > T and -1123 G > C are given in Table 1. PCR was performed using 1 $\mu$L of template DNA (~ 100 ng $\mu$L$^{-1}$), 1 $\mu$L of each primer (10 $\mu$L), 12.5 $\mu$L of master mix, and 7.5 $\mu$L of sterile distilled water in a total volume of 25 $\mu$L. To amplify the fragment containing +1858C > T mutation, the following procedure was conducted: the initial denaturation at 94°C for 4 minutes, 35 cycles including denaturation at 94°C for 30 seconds, the annealing at 60°C for 30 seconds, the extension at 72°C for 30 seconds, and the final extension at 72°C for 5 minutes. To amplify the fragment containing -1123G > C mutation, the following procedure was conducted: the initial denaturation at 94°C for 4 minutes, 35 cycles including denaturation at 94°C for 30 seconds, the annealing at 58°C for 30 seconds,

the extension at 72°C for 30 seconds, and the final extension at 72°C for 5 minutes. Then, the PCR products were electrophoresed on 1.5% agarose gel; the fragment lengths for +1858C > T and -1123G > C were 392 and 171 bp, respectively.

**Table 1.** Characteristics of Forward and Reverse Primers

| Name | Primer Sequence | $T_m$ |
|---|---|---|
| rs2476601-F | 5$'$-TTAGCGCTAGCCTCAATGACGACC-3$'$ | 67.9 |
| rs2476601-R | 5$'$-TGAGCCTCAGACATCTCCAGTCC-3$'$ | 68.3 |
| rs2488457-F | 5$'$-AGCCAACSTCCWCTAAGTGGGCTG-3$'$ | 51.4 |
| rs2488457-R | 5$'$-GAGTTTCCTCTGACTCCATCGCAG-3$'$ | 59.21 |

### 2.3. Digestion

Genotyping PCR products for *PTPN22* mutation was performed using the RFLP method. PCR products containing +1858C > T mutation were digested with the restriction enzyme Rsa1 (Promega GmbH, Germany) in an overnight incubation at 37°C. The reaction included 10 $\mu$L of PCR products, 0.5 $\mu$L (20,000 IU/$\mu$L) of Rsa1, and 2 $\mu$L of buffer in 7.5 $\mu$L of sterile distilled water. PCR products with -1123G > C mutation were digested with the restriction enzyme Sac1 (Promega GmbH, Germany). Especially, the reaction included 10 $\mu$L of PCR products, 0.5 $\mu$L (20,000 IU/$\mu$L) of enzyme Sac1, and 2 $\mu$L of buffer in 7.5 $\mu$L of sterile distilled water. PCR products containing -1123G > C mutation were also digested in an overnight incubation at 37°C. Then, the digested products were electrophoresed on 2.5% agarose gel.

In relation to rs2476601 polymorphism, as shown in Figure 1, the 392-bp PCR products were digested with Rsa1 for each genotype as follows: the homozygous wildtype allele CC had 4 bands of 228, 74, 46, and 44 bp, and heterozygote CT had 5 bands of 272, 228, 74, 46, and 44 bp.

In the case of rs2488457 polymorphism, as shown in Figure 2, after digesting the PCR products with Sac1, the allele -1123G showed a 171-bp band on the gel, while the allele -1123C showed two 147- and 24-bp bands and heterozygote GC had three 171-, 147-, and 24-bp bands; the 24-bp band not observed on agarose gel due to the small size. To verify the results of PCR-RFLP for each polymorphism, 10% of the PCR products were sequenced (Figures 3 and 4).

### 2.4. Statistical Analysis

Data were analyzed with SPSS version 24.0 (IBM SPSS Statistics 24) and the Hardy-Weinberg equilibrium was tested. The continuous data were expressed as mean ± standard deviation (SD) and the frequencies of the alleles

**Figure 1.** RFLP Analysis of *PTPN22* 1858C > T Polymorphism



Lanes 1, 2, 6, and 7 show homozygous individuals with wildtype alleles (CC); lanes 3 - 5 show heterozygous (C/T) individuals.

**Figure 2.** RFLP Analysis of *PTPN22* -1123G > C Polymorphism



Lanes 1 - 3, and 6 show homozygous individuals with wildtype alleles (GG); lanes 4, 5, 8, and 9 show heterozygous GC individuals and lane 7 shows a homozygous individual with CC allele.

and genotypes in patients and controls were compared using chi-square test. Odds ratio (OR) and 95% confidence interval (CI) were calculated. P value of less than 0.05 was considered significant.

**Figure 3.** Sequencing Polymorphism rs2476601, Heterozygous Samples (CT)



**Figure 4.** Sequencing Polymorphism rs2488457, Homozygous Samples (CC)



## 3. Results

The results of clinical and statistical data of patients with SLE are shown in Table 2. Out of 120 patients with SLE tested for anti-dsDNA, 47.5% were positive and 52.5% were negative. Also, among the patients with SLE tested for ANA, 49.2% were positive and 50.8% were negative. The statistical results showed no significant difference in genotype distribution for both +1858C > T (P = 0.551, OR = 1.249, 95% CI = 0.601 to 2.598 and P = 0.502, OR = 1.286, 95% CI = 0.617 to 2.678) and -1123 G > C (P = 0.884, OR = 0.811, 95% CI = 0.049 to 13.512 and P = 0.917, OR = 0.861, 95% CI = 0.052 to 14.347) polymorphisms for the positive patients, compared with the negative ones for ANA and anti-dsDNA factors.

### 3.1. Genotype and Allele Frequencies of the +1858C > T Polymorphism of PTPN22 Gene

The genotype and allele frequencies of +1858C > T in patients with SLE and the controls are shown in Table 3. Geno-

**Table 2.** Comparison of ANA and Anti-dsDNA Factors Between Different Genotypes in the Study Subjects

| Genotype | ANA[a] | | P Value | OR (95% CI) | Anti-dsDNA[a] | | P Value | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| | + | - | | | + | - | | |
| **+1858C > T** | | | | | | | | |
| CC | 35 (29.2) | 37 (30.8) | - | - | 36 (30) | 36 (30) | - | - |
| CT | 22 (18.3) | 26 (21.7) | 0.551 | 1.249 (0.601 - 2.598) | 21 (17.5) | 27 (22.5) | 0.502 | 2.286 (0.617 - 2.678) |
| TT | 0 | 0 | - | - | 0 | 0 | - | - |
| **-1123G > C** | | | | | | | | |
| GG | 29 (24.2) | 22 (18.4) | 0.848 | 1.318 (0.07 - 22.263) | 25 (20.9) | 26 (21.7) | 0.978 | 0.962 (0.057 - 16.223) |
| GC | 25 (30) | 37 (30.8) | 0.884 | 0.811 (0.049 - 13.512) | 31 (25.8) | 36 (30) | 0.917 | 0.861 (0.052 - 14.347) |
| CC | 1 (0.8) | 1 (0.8) | - | - | 1 (0.8) | 1 (0.8) | - | - |

[a]The variables were only assessed the patients and are presented as No. (%).

type frequencies for the *PTPN22* 1858T SNP were in Hardy-Weinberg equilibrium in the controls. The results showed no significant difference between the allele (P < 0.001) and genotype frequencies (P < 0.001). TT and CT genotypes in patients and controls were 40% and 87%, respectively; in addition, the CC genotype significantly increased in patients (72% vs. 33% in controls, P < 0.001, OR = 3.955, 95% CI = 2.300 to 6.801).

### 3.2. Genotype and Allele Frequencies of the -1123G > C Polymorphism of PTPN22 Gene

The genotype and allele frequencies of -1123G > C in patients with SLE and the controls are shown in Table 4. Genotype frequencies for the *PTPN22* 1123G SNP were in the Hardy-Weinberg equilibrium in the controls. Genotype containing allele 1123C (CC and GC) increased in patients with SLE, compared with the controls (57.5% vs. 45.8%); there was no association between the -1123 G > C polymorphism and SLE disease (P = 0.0902, OR = 4.102, 95% CI = 0.794 to 21.193).

## 4. Discussion

The *PTPN22* is recently known as the negative regulator of B- and T-cell receptors in cell signaling pathway. The existence of an allele of *PTPN22* (+1858C > T), participating in the R620W mutation, and the existence of a single nucleotide variant (-1123G > C) of this gene, located on its promoter, were demonstrated in SLE and other autoimmune diseases (16). The *PTPN22* C1858T allele corresponding to R620W amino acid substitution (arginine to tryptophan) was associated with several autoimmune diseases including SLE.

The frequency of *PTPN22* R620W polymorphism is usually very low in general population, but in some regions such as Scandinavia it reaches 15% (17). Various studies showed a heterogeneous allelic distribution in a North-East gradient of the 1858T allele frequency in different populations associated or not associated with *PTPN22* C1858T single nucleotide polymorphism for the autoimmune diseases (18-20). The association between *PTPN22* 1858T and SLE was first reported in white people of North America by Kyogoku et al. (20).

In the present study, the probable association between rs2476601 and rs2488457 polymorphisms of *PTPN22* gene and the risk of SLE were studied in a sample of Iranian population. According to the results, there was relationship in rs2476601 polymorphism (P < 0.001, OR = 0.253, 95% CI = 0.147 to 0.435) and no relationship in rs2488457 polymorphism (P = 0.0902, OR = 4.102, 95% CI = 0.794 to 21.193) and the increased risk of SLE in the studied population. Besides, the comparison of both positive and negative ANA and positive and negative anti-dsDNA genotype frequency in both polymorphisms showed no significant differences. Table 3 shows no relationship between the studied factors and the disease.

Similarly to the results of the current study, Orozco et al., in Span (21), Reddy et al., in Sweden (22) and a study in Egypt (1) confirmed the association between the 1858C > T polymorphism of *PTPN22* gene and the development of SLE in patients. Few studies reported no association between *PTPN22* polymorphism and SLE. Wu et al., reported no association in this regard among patients with SLE living in North America, Finland, and Great Britain (23). Viken et al., reported the results similar to those of Hui on patients with SLE in Norway and Caucasia (24). Also, Aksoy et al., reported no association between *PTPN22* polymorphism and SLE in a study conducted in Turkey (25).

The -1123G > C (rs2488457) is a SNP in the promoter site

**Table 3.** Comparison of the Frequency of rs2476601 Polymorphism Genotypes and Alleles in the Study Subjects

| Variable | Patient, No. (%) | Control, No. (%) | df | P Value | OR | 95% CI | Adjusted OR[a] (95% CI) |
|---|---|---|---|---|---|---|---|
| **Genotype** | | | | | | | |
| CC | 72 (60) | 33 (27.5) | 1 | < 0.001 | 0.253 | 0.147 - .0435 | 0.144 - 0.440 |
| CT | 48 (40) | 87 (72.5) | - | - | - | - | - |
| TT | 0 | 0 | - | - | - | - | - |
| **Allele** | | | | | | | |
| C | 192 (80) | 153 (63.75) | 1 | < 0.001 | 0.44 | 0.291 - 0.663 | - |
| T | 48 (20) | 87 (36.25) | - | - | - | - | - |

[a]The adjusted OR for age and gender.

**Table 4.** Comparison of the Frequency of rs2488457 Polymorphism Genotypes and Alleles in the Study Subjects

| Variable | Patient, No. (%) | Control, No. (%) | df | P Value | OR | 95% CI | Adjusted OR[a] (95% CI) |
|---|---|---|---|---|---|---|---|
| **Genotype** | | | | | | | |
| GG | 51 (42.5) | 65 (54.2) | 1 | 0.307 | 2.354 | 0.456 - 12.156 | 0.412 - 11.716 |
| GC | 67 (55.8) | 49 (40.8) | 1 | 0.092 | 4.102 | 0.794 - 21.193 | 0.732 - 20.814 |
| CC | 2 (1.7) | 6 (5) | - | - | - | - | - |
| **Allele** | | | | | | | |
| C | 169 (70.4) | 179 (74.6) | 1 | 0.307 | 0.811 | 0.543 - 1.212 | - |
| G | 71 (29.6) | 61 (25.4) | - | - | - | - | - |

[a]The adjusted OR for age and gender.

of a *PTPN22*; the DNA sequence around this SNP binds to transcription factor AP4, which can affect mRNA expression, and accordingly, the performance of LYP. In this SNP, missense mutation in -1123 position converts G to C; therefore, the -1123 allele can affect the expression of mRNA of *PTPN22* and cause dysregulation in B- and T-cells of patients with SLE (13). In the white Europeans, *PTPN22* -1123G > C is often expressed with *PTPN22* 1858C > T (20). A study performed by Feng et al., on patients with rheumatoid arthritis in China (26) and another study by Kawasaki et al., in Asian populations such as Japan and Korea showed the association between rs2488457 (-1123G > C) polymorphism and susceptibility to T1DM (27). In a study in Mexico, there was no association between the -1123G > C and +1858C > T and D polymorphisms of *PTPN22* and the development of SLE (13).

The current study was only conducted on a population of Lorestan province, Iran; hence, more studies including global and regional data are necessary to verify the results. In conclusion, the study showed association between the +1858T allele and no association between-1123C allele of *PTPN22*, and SLE in the population of the Southwest of Iran, which in second one (-1123 allele) can be attributed to the

small sample size in the present study. Therefore, further studies on a greater sample sizes are needed to evaluate the association between the patients with SLE and *PTPN22* mutation.

## Footnote

**Ethical Considerations:** This article is approved by Ethics committee of Shahid Chamran Ahvaz University of Medical Sciences with registration number of IR.LUMS.REC.1396.318.

## References

1. Moez P, Soliman E. Association of PTPN22 gene polymorphism and systemic lupus erythematosus in a cohort of Egyptian patients: im-

pact on clinical and laboratory results. *Rheumatol Int*. 2012;**32**(9):2753–8. doi: 10.1007/s00296-011-2063-z. [PubMed: 21818561].

2. Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus. *Genomics Proteomics Bioinformatics*. 2015;**13**(4):210–8. doi: 10.1016/j.gpb.2015.09.001. [PubMed: 26415621].

3. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends Mol Med*. 2010;**16**(2):47–57. doi: 10.1016/j.molmed.2009.12.005. [PubMed: 20138006].

4. Pradhan V, Borse V, Ghosh K. PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility. *J Postgrad Med*. 2010;**56**(3):239–42. doi: 10.4103/0022-3859.68651. [PubMed: 20739780].

5. Chung SA, Criswell LA. PTPN22: its role in SLE and autoimmunity. *Autoimmunity*. 2007;**40**(8):582–90. doi: 10.1080/08916930701510848. [PubMed: 18075792].

6. Chen Z, Zhang H, Xia B, Wang P, Jiang T, Song M, et al. Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis. *Int J Colorectal Dis*. 2013;**28**(10):1351–8. doi: 10.1007/s00384-013-1671-3. [PubMed: 23456301].

7. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. *Annu Rev Immunol*. 2009;**27**:363–91. doi: 10.1146/annurev.immunol.021908.132653. [PubMed: 19302045].

8. Abbasi Z, Kazemi Nezhad SR, Pourmahdi-Broojeni M, Rajaei E. Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran. *Iran Biomed J*. 2017;**21**(1):61–6. doi: 10.18869/acadpub.ibj.21.1.61. [PubMed: 27215233].

9. Kouhpayeh HR, Hashemi M, Hashemi SA, Moazeni-Roodi A, Naderi M, Sharifi-Mood B, et al. R620W functional polymorphism of protein tyrosine phosphatase non-receptor type 22 is not associated with pulmonary tuberculosis in Zahedan, southeast Iran. *Genet Mol Res*. 2012;**11**(2):1075–81. doi: 10.4238/2012.April.27.6. [PubMed: 22614276].

10. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. *J Immunol Res*. 2014;**2014**:419029. doi: 10.1155/2014/419029. [PubMed: 24864268].

11. Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?. *FEBS Lett*. 2011;**585**(23):3689–98. doi: 10.1016/j.febslet.2011.04.032. [PubMed: 21515266].

12. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. *Nat Med*. 2015;**21**(7):730–8. doi: 10.1038/nm.3897. [PubMed: 26121193].

13. Machado-Contreras JR, Munoz-Valle JF, Cruz A, Salazar-Camarena DC, Marin-Rosales M, Palafox-Sanchez CA. Distribution of PTPN22 polymorphisms in SLE from western Mexico: correlation with mRNA expression and disease activity. *Clin Exp Med*. 2016;**16**(3):399–406. doi: 10.1007/s10238-015-0359-0. [PubMed: 26013387].

14. Liu F, Liu J, Zheng TS, Li Q, Wang C, Pan XP, et al. The -1123Ggt;C variant of PTPN22 gene promoter is associated with latent autoimmune diabetes in adult Chinese Hans. *Cell Biochem Biophys*. 2012;**62**(2):273–9. doi: 10.1007/s12013-011-9291-4. [PubMed: 21956362].

15. Shahvali Koohshori M, Kazemi Nezhad SR, Rajaei E, Akhoond MR. Association of the MTHFR C677T polymorphism (rs1801133) with risk of rheumatoid arthritis in the Khuzestan Province of Iran. *Gene Cell Tissue*. 2015;**2**(4). doi: 10.17795/gct-28421.

16. Stanford SM, Mustelin TM, Bottini N. Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. *Semin Immunopathol*. 2010;**32**(2):127–36. doi: 10.1007/s00281-010-0201-4. [PubMed: 20204370].

17. Fousteri G, Liossis SN, Battaglia M. Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. *Clin Immunol*. 2013;**149**(3):556–65. doi: 10.1016/j.clim.2013.10.006. [PubMed: 24269925].

18. Ikari K, Momohara S, Inoue E, Tomatsu T, Hara M, Yamanaka H, et al. Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population. *Rheumatology (Oxford)*. 2006;**45**(11):1345–8. doi: 10.1093/rheumatology/kel169. [PubMed: 16690758].

19. Hashemi M, Atabaki M, Daneshvar H, Zakeri Z, Eskandari-Nasab E. Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheumatoid arthritis in Zahedan, Southeast Iran. *Int J Immunogenet*. 2013;**40**(4):299–305. doi: 10.1111/iji.12038. [PubMed: 23350658].

20. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. *Am J Hum Genet*. 2004;**75**(3):504–7. doi: 10.1086/423790. [PubMed: 15273934].

21. Orozco G, Sanchez E, Gonzalez-Gay MA, Lopez-Nevot MA, Torres B, Caliz R, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Rheum*. 2005;**52**(1):219–24. doi: 10.1002/art.20771. [PubMed: 15641066].

22. Reddy MV, Johansson M, Sturfelt G, Jonsen A, Gunnarsson I, Svenungsson E, et al. The R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1. *Genes Immun*. 2005;**6**(8):658–62. doi: 10.1038/sj.gene.6364252. [PubMed: 16052172].

23. Wu H, Cantor RM, Graham DS, Lingren CM, Farwell L, Jager PL, et al. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. *Arthritis Rheum*. 2005;**52**(8):2396–402. doi: 10.1002/art.21223. [PubMed: 16052563].

24. Viken MK, Amundsen SS, Kvien TK, Boberg KM, Gilboe IM, Lilleby V, et al. Association analysis of the 1858Cgt;T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. *Genes Immun*. 2005;**6**(3):271–3. doi: 10.1038/sj.gene.6364178. [PubMed: 15759012].

25. Aksoy R, Duman T, Keskin O, Duzgun N. No association of PTPN22 R620W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus. *Mol Biol Rep*. 2011;**38**(8):5393–6. doi: 10.1007/s11033-011-0692-7. [PubMed: 21384170].

26. Feng X, Li YZ, Zhang Y, Bao SM, Tong DW, Zhang SL, et al. Association of the PTPN22 gene (-1123G gt; C) polymorphism with rheumatoid arthritis in Chinese patients. *Tissue Antigens*. 2010;**76**(4):297–300. doi: 10.1111/j.1399-0039.2010.01521.x. [PubMed: 20604892].

27. Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T, Nakanishi K, et al. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. *Am J Med Genet A*. 2006;**140**(6):586–93. doi: 10.1002/ajmg.a.31124. [PubMed: 16470599].